ksilink
from patient to drug

Patient-based drug discovery

for better drug candidates in high-medical-need CNS indications

Summer 2025

Lack of efficacy accounts for 57% of late-stage clinical trial failures, rising to 71% in the central nervous system (CNS) therapeutic area.



Why is **EFFICACY** the primary cause of high attrition rates in clinical trials?

1. Inadequate understanding of disease mechanisms
2. Selection of inappropriate or ineffective biological targets
3. Use of animal models that poorly replicate human disease conditions

Ksilink addresses the problem of late-stage failure through patient-based drug discovery.

Source: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2565686

Patient-based drug discovery uses patient-derived cellular models for phenotypic screening.

EXAMPLE: CNS disorder



Disease model established at KSILINK based on patient-derived diseased cortical neurons with an isogenic healthy control.

PATIENT-BASED DRUG DISCOVERY: Identification of compounds that shift the diseased towards the healthy phenotype

Ksilink overcomes the complexity of patient-based drug discovery, unlocking higher throughput.

By automating patient-based cellular disease models with AI-powered image analysis, Ksilink uniquely solves three major challenges in phenotypic drug discovery.

Physiological Relevance



Human disease models derived from patients

Stem cell derived or from other sources

Phenotypic Characterization



AI-powered image analysis

Enabling assay automation (384 – 1,536 plates)

Throughput Feasibility



Rigourous industry standard automation

Screening of large chemical libraries + genetic pertubators

Ksilink's platform generates first-in-class Hit series with improved clinical success rate.

Our platform can be utilized for simultaneous Hit and Target identification.



Ksilink delivers disease relevant Hit series with a strong Target hypothesis to be validated in orthogonal systems. Our models and technical skills further support Lead generation and optimization.

While open for strategic collaborations with industry partners, we have started to develop our own pipeline and selected programs that address significant unmet medical need.

CURRENT FOCUS

Parkinson's Disease

Goal: Decrease aSyn protein expression and improve overall neuronal health

Stage: Hit&Target validation

Autism Spectrum Disorders

Goal: Synaptic disorder rescue with SHANK3 stimulation in patient-based neurons

Stage: Hit&Target validation

NEXT GENERATION

Amyotrophic Lateral Sclerosis

Goal: TBK1 upregulation with focus on lysosomal activity

Stage: Disease modeling

Neuroinflammation



Goal: Identify inflammation-related microglia substrates and microglia-specific NLRP3 inhibitors

Stage: Automated System

CUSTOMER DRIVEN

Programs paid by customers

Ksilink is searching for strategic collaborations with industry partners.

Ksilink will deliver significant milestones in the next 3-4 years, leveraging our proven phenotypic drug discovery engine.

We will deliver significant milestones in the next 3-4 years, leveraging our proven phenotypic drug discovery engine.



Back a therapeutic platform that identifies novel drug candidates in predictive human models. Designed to boost success where most fail, in Phase 2 and 3.

- ✓ Unleash phenotypic screening thanks to predictive human models and AI.
- ✓ CNS pipeline launched with Autism and Parkinson. More programs ready.
- ✓ Built entirely on non-dilutive funding. More underway (EIC €2.5M+).
- ✓ Scalable platform: different cell types and modalities.
- ✓ Seasoned, multidisciplinary Team.



Meet the team that translates Science into Assets

Management team

Antoine DE LACOMBE, Co-founder
Chief Executive Officer & Finance
20+ years in Finance & Corporate finance in private sector

Dr. Mona BOYÉ, Co-founder
Chief Business Officer
20+ years in tech transfer & partnerships

Dr. Helmut HANING
Chief Operations Officer
30+ years in Pharma,
Ex-Global Head of Chemistry at BAYER

Dr. Johannes WILBERTZ
Director of R&D
15+ years experience in CNS disease modeling & data science

Advisors

Dr. Ulf NERHBASS
Scientific Advisor of Ksilink
CEO at Luxemburg Institute of Health
Founder of Qurient Thx > **IPO in 2016**
Ex-CEO at Institut Pasteur Korea

Dr. Alleyn PLOWRIGHT
CSO at PANGEA BIO Ltd
Former Head of Integrated Drug Discovery at SANOFI

Prof. Dr. Thomas THUM
Founder at CARDIOR
> **NovoNordisk deal €1Bn+ in 2024**
Prof. at Hannover Medical School

Dr. Thierry DORVAL
Head of Data Sciences & Data Management at SERVIER

Executive Summary

Who we are

We are a French TechBio company with **unique expertise for AI-enabled high-throughput phenotypic screening of patient-based cellular disease models**.

What we do

We decipher and automate complex human cell biology *in vitro* to deliver **novel drug candidates with higher success rates in patients**.

Our mission

We aim to establish ourself as a leading patient-centered TechBio to discover and **develop novel drug candidates for high medical-need CNS disorders** (others pending).

Our network

Emerged from a public private ecosystem, we access innovation via our world-class **network of European Institutes and Hospitals**.

We open our share capital for pre-seed /seed investment to become the leading patient-centered discovery engine for novel drug candidates.

ksilink
from patient to drug

Come and meet us in our offices and labs in Strasbourg, France





ksilink
from patient to drug

Contacts:


Antoine DE LACOMBE
Chief Executive Officer
+33 6 26 94 37 88
antoine.delacombe@ksilink.com


Dr. Mona BOYÉ
Chief Business Officer
+33 06 88 26 64 04
mona.boye@ksilink.com


Dr. Helmut Haning
Chief Operation Officer
+49 1515 8549863
helmut.haning@ksilink.com

Pictures created in https://BioRender.com